JP2016506391A5 - - Google Patents

Download PDF

Info

Publication number
JP2016506391A5
JP2016506391A5 JP2015546449A JP2015546449A JP2016506391A5 JP 2016506391 A5 JP2016506391 A5 JP 2016506391A5 JP 2015546449 A JP2015546449 A JP 2015546449A JP 2015546449 A JP2015546449 A JP 2015546449A JP 2016506391 A5 JP2016506391 A5 JP 2016506391A5
Authority
JP
Japan
Prior art keywords
composition
disease
use according
subject
insulin resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015546449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506391A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/036214 external-priority patent/WO2014088631A1/en
Publication of JP2016506391A publication Critical patent/JP2016506391A/ja
Publication of JP2016506391A5 publication Critical patent/JP2016506391A5/ja
Pending legal-status Critical Current

Links

JP2015546449A 2012-12-06 2013-04-11 ペプチド治療薬およびその使用方法 Pending JP2016506391A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734293P 2012-12-06 2012-12-06
US61/734,293 2012-12-06
PCT/US2013/036214 WO2014088631A1 (en) 2012-12-06 2013-04-11 Peptide therapeutics and methods for using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017146044A Division JP2018021033A (ja) 2012-12-06 2017-07-28 ペプチド治療薬およびその使用方法

Publications (2)

Publication Number Publication Date
JP2016506391A JP2016506391A (ja) 2016-03-03
JP2016506391A5 true JP2016506391A5 (enExample) 2016-06-02

Family

ID=49549068

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015546449A Pending JP2016506391A (ja) 2012-12-06 2013-04-11 ペプチド治療薬およびその使用方法
JP2017146044A Pending JP2018021033A (ja) 2012-12-06 2017-07-28 ペプチド治療薬およびその使用方法
JP2018208926A Pending JP2019069942A (ja) 2012-12-06 2018-11-06 ペプチド治療薬およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017146044A Pending JP2018021033A (ja) 2012-12-06 2017-07-28 ペプチド治療薬およびその使用方法
JP2018208926A Pending JP2019069942A (ja) 2012-12-06 2018-11-06 ペプチド治療薬およびその使用方法

Country Status (7)

Country Link
US (3) US20130303436A1 (enExample)
EP (3) EP3287172A1 (enExample)
JP (3) JP2016506391A (enExample)
CN (1) CN104994912A (enExample)
CA (1) CA2894182A1 (enExample)
HK (1) HK1215934A1 (enExample)
WO (1) WO2014088631A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4397314B1 (en) * 2012-10-22 2025-12-03 Stealth BioTherapeutics Inc. Treatment of left ventricular remodeling
WO2015057315A1 (en) * 2013-09-04 2015-04-23 Kelly Joseph Michael Lawless Methods and systems for the detection of disease
WO2015089316A1 (en) * 2013-12-12 2015-06-18 Cornell University Methods for preventing and treating oral cancers
CA2933405A1 (en) * 2013-12-13 2015-06-18 Medimmune Limited Protease-resistant peptides
EP3082838A4 (en) * 2013-12-16 2017-07-26 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
CN106132984B (zh) * 2013-12-27 2020-12-08 康德生物医疗技术公司 药学相关的芳香族阳离子肽
CN106459169A (zh) * 2014-03-03 2017-02-22 康德生物医疗技术公司 药学上相关的芳香族阳离子肽
WO2015183970A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including flavonoid and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2015183988A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including therapeutic small molecules and uses thereof
US10576124B2 (en) * 2014-05-28 2020-03-03 Stealth Biotherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
WO2015183963A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2015183985A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including naphthoquinones and uses thereof
US10627392B2 (en) 2014-06-17 2020-04-21 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
US10744178B2 (en) * 2014-08-21 2020-08-18 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US12472157B2 (en) 2014-11-07 2025-11-18 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa with n-acetylcysteine amide
US12667548B2 (en) 2014-11-07 2026-06-30 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide
WO2016077422A1 (en) * 2014-11-11 2016-05-19 The Johns Hopkins University Biomarkers useful in the treatment of subjects having retinits pigmentosa
US11268964B2 (en) * 2014-11-11 2022-03-08 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
JP6854771B2 (ja) * 2015-03-06 2021-04-07 ステルス バイオセラピューティックス コープ 薬学的に適切なペプチドを調製するための方法
WO2016190852A1 (en) * 2015-05-26 2016-12-01 Stealth Peptides International, Inc. Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
WO2016195663A1 (en) * 2015-06-02 2016-12-08 Stealth Peptides International, Inc. Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
AU2016379403B2 (en) * 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
ES3057779T3 (en) 2016-01-15 2026-03-04 Childrens Medical Ct Corp Therapeutic use of mitochondria and combined mitochondrial agents
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
CN105987839B (zh) * 2016-06-03 2018-09-28 浙江世纪康大医疗科技股份有限公司 一种edta-柠檬酸抗原修复液
CN105987840B (zh) * 2016-06-03 2018-09-28 浙江世纪康大医疗科技股份有限公司 一种柠檬酸抗原修复液
WO2017210668A1 (en) * 2016-06-03 2017-12-07 Jt Pharmaceuticals, Inc. Sustained release compositions of kappa-opioid receptor agonist
CN107042067B (zh) * 2017-05-24 2019-11-08 天津大学 聚硅氧烷-金属有机框架材料杂化渗透蒸发复合膜及其制备与应用
CA3067890A1 (en) * 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
EP3443980A1 (en) * 2017-08-15 2019-02-20 Ciliocure Limited Compound for the treatment of patients with leptin-resistant obesity, bardet-biedl syndrome and other ciliopathies
CA3079196C (en) 2017-09-20 2021-05-18 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
US12662449B2 (en) 2017-09-20 2026-06-23 Nacuity Pharmaceuticals, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US11091433B2 (en) 2017-09-20 2021-08-17 Nacuity Pharmaceutials, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US11548851B2 (en) 2017-09-20 2023-01-10 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
WO2019201333A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
AU2020206139A1 (en) 2019-01-11 2021-07-29 Nacuity Pharmaceuticals, Inc. Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with N-acetylicysteine amide (NACA) or 2R,2R')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (diNACA)
JP7631200B2 (ja) 2019-01-11 2025-02-18 ナキュイティ ファーマシューティカルズ， インク． 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ）
JP7638265B2 (ja) * 2019-07-24 2025-03-03 ステルス バイオセラピューティクス インコーポレイテッド 神経変性疾患の治療におけるペプチド模倣化合物（ｒ）－２－アミノ－ｎ－（（ｓ）－ｌ－（（（ｓ）－５－アミノ－ｌ－（３－ベンジル－１，２，４－オキサジアゾール－５－イル）ペンチル）アミノ）－３－（４－ヒドロキシ－２，６－ジメチルフェニル）－ｉ－オキソプロパン－２－イル）－５－グアニジノペンタンアミド
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
KR102503914B1 (ko) * 2020-09-01 2023-02-24 인제대학교 산학협력단 황반변성 세포모델의 제조방법
US20230381281A1 (en) * 2020-10-16 2023-11-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases
KR20230125802A (ko) * 2020-12-11 2023-08-29 아이피2아이피오 이노베이션스 리미티드 신규 화합물
CN112618966B (zh) * 2020-12-18 2023-07-28 北京宏强富瑞技术有限公司 一种多波长激光针刺仪
CN113421648B (zh) * 2021-06-21 2024-04-23 中国科学院北京基因组研究所(国家生物信息中心) 一种用于预测射血分数保留型心衰风险的模型
CN113588375B (zh) * 2021-08-20 2023-09-29 中科光华(西安)智能生物科技有限公司 一种高稳定性骨及骨肿瘤组织微阵列芯片及其制备方法
CN116262134A (zh) * 2021-12-15 2023-06-16 联邦生物科技(珠海横琴)有限公司 一种稳定的多剂量给药的glp-1受体激动剂的制剂及其制备方法和应用
CN114480449A (zh) * 2022-03-17 2022-05-13 天津医科大学总医院 布拉氏酵母菌CNCMI-745衍生蛋白Trx2及其在制备防治腹泻药物中的应用
CN114949184A (zh) * 2022-05-13 2022-08-30 华中科技大学同济医学院附属同济医院 Glp-1代谢物在制备减轻急性肾损伤药物中的用途
US20260165992A1 (en) * 2024-12-13 2026-06-18 Neuronasal, Inc. Treatment of central nervous system diseases with n-acetylcysteine and glucagon-like peptide-1 receptor agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
PT1263464E (pt) 2000-03-09 2012-12-17 Genzyme Corp Utilização de anticorpos anti-tgf-beta antagonistas para tratar ou para prevenir a perda da função renal
CA2447008A1 (en) 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
EP1411968B1 (en) * 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
EP1701731A4 (en) 2003-12-12 2009-08-05 Einstein Coll Med GLP-1 (9-36) METHOD AND COMPOSITIONS
US20090202497A1 (en) * 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
US20100286029A1 (en) * 2007-09-11 2010-11-11 Dorian Bevec Use of a peptide as a therapeutic agent
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
DK2344519T3 (en) 2008-11-07 2017-01-23 Massachusetts Gen Hospital C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1)
CA2770688C (en) * 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
CN102614514B (zh) * 2011-01-26 2014-12-10 王永祥 Glp-1受体激动剂用于治疗疼痛

Similar Documents

Publication Publication Date Title
JP2019507781A5 (enExample)
JP2007503469A (ja) アミロイド症およびそれに関連した疾患を改善するための作用物質としてのｒａｇｅアンタゴニスト
AU2004298393A1 (en) Copper antagonist compounds
CN104869993A (zh) 治疗阿尔茨海默病及相关疾病的组合疗法
CA3148119A1 (en) Dosing regimens for oral complement factor d inhibitors
WO2011028794A2 (en) Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
AU2019214557A1 (en) Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
JP2013515739A5 (enExample)
CN113546082B (zh) 特拉匹韦在制备治疗缺血/再灌注损伤的药物及细胞保护药物中的应用
KR20220042480A (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
US20240415973A1 (en) Uses of hyaluronan conjugates
CN112351975B (zh) 过氧化物酶体增殖物活化受体α的激动剂和使用方法
JP2025161811A (ja) タウオパチーを処置するためのペプチド組成物及び方法
JP7702883B2 (ja) 神経変性疾患、好ましくはアルツハイマー病を治療するための２－フェニル－６－（１ｈ－イミダゾール－１－イル）キナゾリンの使用
DE69508551T2 (de) Verwendung von L-Carnitin und Derivaten zur Verringerung der Toxizität von Cyclosporin-A und anderer Immunosuppressiva
Guo The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
WO2017006254A1 (en) Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
US20070213366A1 (en) Treatment of Synucleinopathies
PH12017501112A1 (en) Synthetic apelin fatty acid conjugates with improved half-life
US20220062255A1 (en) Treatment of neurodegenerative eye disease using pridopidine
US20230338348A1 (en) Renin-angiotensin system (ras) modulators for treatment of viral infections, pharmaceutical compositions including the same, and methods of treating using the same
CN111132677A (zh) 西尼莫德的给药方案
CN113975276B (zh) 考比替尼在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用
JP2022529742A (ja) 神経修復方法
CN115212194A (zh) 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用